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Abstract
The human microbiome has become a recognized factor in promoting and maintaining health. We 
outline opportunities in interdisciplinary research, analytical rigor, standardization, and policy 
development for this relatively new and rapidly developing field. Advances in these aspects of the 
research community may in turn advance our understanding of human microbiome biology.
It is now widely recognized that disturbances in our normal microbial populations may be 
linked to acute infections such as Clostridium difficile and to chronic diseases such as heart 
disease, cancer, obesity, and autoimmune disorders (Clemente et al., 2012). This has 
prompted substantial interest in the microbiome from both basic and clinical perspectives. 
Although our genome is relatively static throughout life, each of our microbial communities 
changes profoundly from infancy through adulthood, continuing to adapt through ongoing 
exposures to diet, drugs and environment. Understanding the microbiome and its dynamic 
nature may be critical for diagnostics and, eventually, interventions based on the 
microbiome itself. However, several important challenges limit the ability of researchers to 
enter the microbiome field and/or conduct research most effectively.
FUNDAMENTAL CHALLENGES
Many microbiome studies to date have focused on finding patterns, and moving towards 
mechanism remains a major challenge. Once the “natural history” is better characterized 
(research to date has focused on a few locations in the Western world leaving much to 
described), the next step is to test for causality: when cases and controls differ, does the 
microbiome cause the phenotypic change, does the phenotype drive a change in the 
microbiome, or are there feedback loops between the two? Determining which factors in a 
complex ecosystem are most associated with important differences is necessary for the 
development of diagnostic or therapeutic strategies. For example, is the species membership, 
gene functional profile, transcript or protein expression, metabolite profile, or a combination 
thereof indicated in a particular condition? In this context, study designs that allow causal 
inference, such as prospective longitudinal studies and randomized, controlled experimental 
designs are crucial.
Current microbiome studies tend to take either top--down or bottom--up perspectives. The 
former constitutes ecological or systems--level investigations of entire microbial 
communities, while the latter focus on mechanistic examinations of the effects of individual 
microbes, genes, or metabolites. For example, observations of whole--community changes 
associated with obesity are now quite robust (Ley et al., 2005). The latter focuses on a more 
detailed level, where several representative studies have been very successful in identifying 
microbial effects in drug responses, such as the role of specific strains of the gut 
Actinobacterium Eggerthella lenta in inactivating the cardiac glycoside drug digoxin 
(Haiser et al., 2013) and of p-cresol production by certain gut bacteria interfering with host 
detoxification of acetaminophen (Clayton et al., 2009). The dynamic nature of the 
microbiome thus requires scientific approaches that incorporate aspects both of genetics and 
of functional molecular studies into the experimental design. For example, integration of 
ecology with molecular mechanism has identified gut microbial metabolism as a potential 
Huttenhower et al. Page 2
Cell. Author manuscript; available in PMC 2014 November 06.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
impediment in the use of therapeutic food for treatment of severe malnutrition in Malawi 
(Smith et al., 2013), for example. Connecting top--down and bottom--up strategies to 
determine specific mechanism as well as patterns of association is thus a key goal for the 
field moving forward.
ASSAYING AND UNDERSTANDING THE MICROBIOME
Studies of the microbiome share, and in some cases magnify, hurdles common to many 
current ‘omics fields. The cost of sequencing is dropping much faster than the cost of 
analysis, creating a bottleneck in computation. Improved algorithms, increased personnel 
trained in analysis of microbiome data, and access to free or inexpensive computing power 
such as cloud-based resources would all help. Other technical challenges are unique to the 
study of microbial communities. For example, because of the remarkable variation in the 
microbiome between body sites, ages, locations, lifestyles, diets, and host genetics, our 
definitions of “baseline” must continue to be expanded to survey the worldwide microbiome 
in health and its perturbations in disease. This is true for all microbial components: viruses, 
phage, eukaryotes, and archaea, as well as bacteria.
Neither the data generation platforms nor the analysis methods used with the microbiome 
have yet reached the level of refinement necessary for translational applications and 
systematic meta--analyses, as has been achieved in other ‘omics areas such as gene 
expression or genetics over many years of study. Unfortunately, there are not as yet uniform 
standards for how data are deposited and how experiments are described. Data centralization 
efforts such as the NCBI Short Read Archive (SRA), database of Genotypes and Phenotypes 
(dbGaP), and BioSample must balance extremely broad accessibility - being all things to all 
people - with the practical concerns necessary to easily deposit and retrieve individual 
studies’ files. The diversity and lack of standards in human microbiome research has 
resulted in little consistency in how data are deposited in these repositories, and many 
incompatible file formats and conventions are currently in use. Consequently, it is very 
difficult to reconcile data from different studies, even when the same phenotypes are 
available. At the level of sequences deposited within these resources, field--specific 
considerations such as barcoding and primers are not a part of the overall repository design 
and may not be described well in metadata, leading to considerable challenges in 
interpretation. The dataset resulting from the Human Microbiome Project (HMP) is one of 
the largest such examples to date, where the automated deposition pipelines of multiple 
sequencing centers resulted in a variety of files, some from re-sequencing of the same 
sample and some containing as few as a single read after human read filtering (Human 
Microbiome Project Consortium, 2012). For scientists who want to use such data products 
for downstream research, even large datasets from individual projects thus pose a major data 
integration challenge.
The microbiome of each subject exists in a demographic, environmental and clinical 
context; the more precise the definition of clinical phenotypes and natural history, the 
greater the analytic potential, particular in comparisons between studies. Comparison of data 
and metadata between human microbiome studies is also susceptible to batch effects (where 
samples processed at the same time appear to be different due to technical variation) and 
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other technical challenges. Precise descriptions of phenotype, reproducible study designs, 
and standardizing sampling techniques are thus important for assessing variability due to 
technical effects, sampling bias, and other factors.
Standardization of phenotype and sample processing is of critical importance, but the 
development of controlled vocabularies (and tools to applying controlled vocabularies) is 
not complete. One ontology used with the microbiome, EnvO, was originally developed for 
environmental microbial communities and only partially resolves these problems 
(Hirschman et al., 2008); synonyms or near- synonyms are common, such as “stool”, 
“feces”, “faeces”, “gut”, etc. Likewise the gut has been annotated as a “Moist Tropical 
Environment” in some datasets, but this is likely not the intended biome description. 
Documentation supporting the use of the MIxS standard for the human microbiome 
community and improved user interfaces for tools that allow annotation and deposition of 
standards--compliant data could resolve a major bottleneck in current studies (Yilmaz et al., 
2011). Similarly, the PhenX project, which identifies a common set of phenotype variables 
that are useful across many studies (Pan et al., 2012), provides a model for how microbiome 
metadata could be annotated. Adherence to the PhenX standard and to obtaining BioSample 
identifiers that are stable across multiple analyses of the same specimen will be especially 
useful for complex multi’omic studies (Barrett et al., 2012), as well as for systematic meta--
analysis of datasets where statistical power is limited due to small population sizes in 
individual studies. This is especially important if microbiome data are to become more 
rapidly applicable in clinical settings and in large--scale epidemiological studies.
HUMAN STUDIES ISSUES AND POTENTIAL SOLUTIONS
Particularly in the United States, many opportunities exist to streamline microbiome 
research efforts among institutions, at the national level, and for international collaborations. 
For example, there are significant duplications of effort and inconsistencies resulting as 
individual microbiome researchers consult with their local IRBs (Institutional Review 
Boards) or other ethics committees, in part because microbiome studies are so new and do 
not exactly fit the model of either human genetics or microbiological research. This is 
particularly true for fecal microbiota transplantation, which has been increasingly 
implemented into clinical practice with neither clear regulatory guidelines nor a transparent 
facilitation of the associated research opportunities for making causal connections between 
the microbiota and host physiology. Efforts initiated by the NIH’s Clinical and Translational 
Science Award program, such as IRBShare, may be particularly applicable to the 
microbiome to increase communication and sharing of best practices between IRBs in multi-
site studies. Registries designed to simplify recruiting clinical research volunteers are now 
common and provide the added benefit of linking diverse projects across a national research 
network (Richesson and Vehik, 2010). As a research community, we should consider 
systems such as these to streamline subject recruitment, because they have been shown to 
increase study enrollment and lower costs. Methods used in combination with automated 
eligibility screening to identify clinical participants could also be employed to simplify 
recruitment (Beauharnais et al., 2012; Pressler et al., 2012).
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Privacy concerns unique to human-associated microbial communities introduce another 
challenge for microbiome research. For example, in the HMP, the identifier of the 
sequencing machine generating each dataset was access--restricted, because this seemingly--
innocuous information could be associated with a sequencing center and thus the location of 
the donor individual (although de minimis risk guidelines have since been developed 
(Rhodes et al., 2011)). Although consistency and streamlining of IRBs is an ongoing effort 
in many fields, there is as yet little understanding of the subject protection ramifications of 
releasing individual sets of host--associated microbial sequences. For many subjects enrolled 
under earlier protocols, it is often possible to release only aggregate data, not detailed 
clinical information that could theoretically be combined with ‘omics to allow the 
identification of individual subjects. dbGAP, the protected--access database for sensitive 
biomedical information (Mailman et al., 2007), plays an important role but can be 
cumbersome to work with due to regulatory compliance and implementation complexity. 
The generation of large, free, and open IRB--approved high--dimensional datasets will lead 
to substantial advances across the board, both in the human microbiome and other areas of 
modern genomic medicine.
Human microbiome studies are not unique to any one NIH institute or center (IC), and they 
are currently supported by over a dozen ICs. This diversity in research initiatives is exciting, 
but cultural differences between ICs with respect to data sharing, accessibility and patient 
confidentiality are a concern. A recently formed Trans--NIH Microbiome Working Group is 
expected to be especially valuable in harmonized policy development between ICs, as well 
as identifying opportunities to that broaden access to data and increase reusability of results. 
Additional instruction to federal grant review committees on the interpretation and benefit of 
‘omics approaches that complement traditional genetic approaches would also help advance 
microbiome research, as would dedicated study sections with members that span the broad 
range of expertise required to adequately assess such studies. Negotiating interoperability 
within and across the NIH and other federal agencies will have a disproportionately large 
and positive effect on microbiome research because it will eliminate the need for a large 
number of pairwise negotiations on a case--by--case basis.
PROSPECTS FOR THE FUTURE
Despite all the challenges, there is immense potential for microbiome research. Significant 
gains will be achieved with modest investments in training, improved submission tools, 
increased metadata utilization, and resources such as standardized reagents, protocol 
registries or reference datasets. Online tutorials with example data, webinars, virtual 
machines and packaged software encapsulating data and methods for reproducibility, and 
public computing environments such as the DIAG [http://diagcomputing.org] - which is 
specifically designed for data-rich tasks such as those encountered in metagenomics - will 
all play important roles. Experimental design guidelines, adequate power calculations, and 
basic improvements to data submission tools are critical - yet very difficult to achieve in the 
current funding climate - we must facilitate communication within the human microbiome 
research community to overcome this. When we do, we will make it much easier for 
investigators at all levels to enter the field, and to propagate standards and best practices 
within the field.
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Thus while diverse microbial communities inhabit many locations of our bodies - and appear 
to be associated with a spectrum of diseases - it will be the organization of our communities 
of researchers and funding agency program managers that will ultimately improve human 
health. Practically speaking, standardization at every level will enhance the application of 
both top--down and bottom--up microbiome research. We believe that if the 
recommendations we propose are implemented, the field will simultaneously be in a position 
to make efficient use of existing resources, to consistently design, execute, and share new 
study results, and to realize the full potential of improved outcomes for a broad range of 
human diseases.
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